Trials / Unknown
UnknownNCT04747093
Induced-T Cell Like NK Cells for B Cell Malignancies
Induced-T Cell Like NK Cellular Immunotherapy for Refractory B Cell Malignancies
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Relapsed and refractory B cell malignancies show unfavorable prognosis, especially for adult patients. Now, there is no standard management for these patients. Induced-T cell-like NK cells with chimeric antigen receptor (CAR-ITNK cells) is a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of CAR-ITNK cells infusions in patients with relapsed and refractory B cell malignancies.
Conditions
- B Cell Leukemia
- B Cell Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- B-cell Lymphoma Recurrent
- B-cell Lymphoma Refractory
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAR-ITNK cells | CAR-ITNK cells will be infused over 10-15 minutes on Day 0. |
Timeline
- Start date
- 2021-01-29
- Primary completion
- 2021-12-31
- Completion
- 2022-03-31
- First posted
- 2021-02-10
- Last updated
- 2021-02-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04747093. Inclusion in this directory is not an endorsement.